← Back to Clinical Trials
Recruiting NCT03303833

NCT03303833 The GEOLynch Cohort Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03303833
Status Recruiting
Phase
Sponsor Wageningen University
Condition Lynch Syndrome
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2006-07-01
Primary Completion 2030-12

Trial Parameters

Condition Lynch Syndrome
Sponsor Wageningen University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2006-07-01
Completion 2030-12
Interventions
No intervention, observational study.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The GEOLynch cohort study has been established to investigate the influence of genetic, environmental and other factors on tumour risk in persons with Lynch syndrome.

Eligibility Criteria

Inclusion Criteria: * Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene. * Aged between 18 and 80 years at inclusion. Exclusion Criteria: * Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP) * (Chronic) Inflammatory bowel disease * Non-Dutch speaking * Dementia or another mental condition that makes it impossible to fill out questionnaires * Terminally ill persons

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology